ANTICOV
Large Clinical Trial in Africa on the Treatment of Mild Cases of COVID-19
- Durada
- 24/11/2020 - 30/5/2022
- Coordinador
- Drugs for Neglected Diseases initiative (DNDi)
- Finançadors
- German Federal Ministry of Education and Research (BMBF) through a credit for reconstruction (KfW) and the global health agency Unitaid, as part of ACT-A
- Pàgina web
- https://anticov.org/news/
The aim of the ANTICOV clinical trial is to respond to the urgent need to identify treatments that can be used in the early treatment of mild to moderate cases of COVID-19 to prevent hospitalisation surges that could overwhelm fragile and overburdened health systems in Africa.
The clinical trial will be carried out at 19 sites in 13 African countries by the ANTICOV consortium, which includes 26 African organisations and well-known international research and development institutions, including ISGlobal. The project is being coordinated by the Drugs for Neglected Diseases initiative.
ANTICOV will assess the safety and efficacy of different treatments in 2000 to 3000 patients with mild to moderate disease who have not been hospitalised. Trials will take place in Burkina Faso, Cameroon, Côte d’Ivoire, Ethiopia, Ghana, Guinea, Equatorial Guinea, Kenya, Mali, Mozambique, the Democratic Republic of Congo (DRC), Sudan and Uganda. The aim is to ascertain whether early treatment can prevent progression of COVID-19 to severe disease and potentially limit transmission.
ISGlobal’s role in the ANTICOV project is twofold. First, the Institute will work together with two of the hospitals where clinical trials are being carried out, both located in Mozambique: the Manhiça Health Research Centre (CISM) and the Centro de Investigação e Treino em Saúde da Polana Caniço (CISPOC), which forms part of the country’s National Institute of Health.
In addition, ISGlobal is co-leader, together with the Institute of Tropical Medicine (ITM) in Antwerp (Belgium), of one of the project’s two ancillary studies. This is an immunology study that will be carried out in 7 countries to analyse whether the treatments tested in the clinical trial in patients with mild to moderate COVID-19 alter the strength or duration of immune responses to SARS-CoV-2. The researchers will study antibodies and T-lymphocytes and compare the immune responses of symptomatic and asymptomatic patients
Our Team
PI
-
Denise Naniche Directora científica
Co-PI and Technical coordinator
-
Elisa López Assistant Research Professor
Scientific Leader of the IMMUNO study and Co-PI of the IMMUNO Study
-
Gemma Moncunill Assistant Research Professor
Team
-
Sheila Fernández-Luis Medical Research Fellow
-
Daniel Iñiguez Monitor d'assajos clínics
-
Quique Bassat ICREA Research Professor, Director del Programa de Malària
-
Laura De La Fuente Investigadora postdoctoral
-
Carole Amroune Assessora de Cartera
-
Elisabeth Salvo Project manager
Altres projectes
Veure projectes passatsINTE-AFRICA
Integrating and decentralizing diabetes and hypertension services in Africa
COMBACTE
Combatent la Resistència Bacteriana a Europa
Desenvolupament d'estratègies per a l'Eradicació de la Malaltia de Pian
Eradicació del Pian
Novel Marine Biomolecules against Biofilm (NoMorFilm)
Application to medical devices
COMBACTE-CARE
Combatting Bacterial Resistance in Europe - Carbapenem Resistance
Prioritising Antimicrobial Resistance: establishing an interdisciplinary International Research Partnership to tackle an evolving global health threat
An interdisciplinary International Research Partnership to tackle an evolving global health threat
Development of new metal-antibiotics against pathogens causing chronic infections in patients with cystic fibrosis.
New metal-antibiotics for patients with cystic fibrosis
HU-MEN (High frequency Ultrasound-based MENingitis screening)
Non-invasive ultrasound-based screening for meningitis: Proof-of concept in infants
Xpatial-TB
Improved case detection through TB contact risk stratification by Xpert results and spatial parameters in Mozambique
WHIP3TB
Evaluation of the effect of weekly high dose rifapentine and isoniazid (3HP) vs periodic 3HP vs 6H for preventing TB among HIV-positive individuals
New antibacterial agents against 'Acinetobacter baumannii'
Search for new target proteins and use of antibacterial or inhibitory peptides against resistance mechanisms in 'Acinetobacter baumannii'
Desarrollo de nuevos metaloantibióticos frente a patógenos causantes de infecciones crónicas en pacientes con fibrosis quística
VINCI
Optimizing provider-initiated HIV testing, linkage, and retention in care in the district of Manhiça, Mozambique
AVATAR
Searching the hidden: evaluating dengue, chikungunya and Zika autochthonous transmission in the city of Barcelona.
COVID-PREG
Eficacia de hidroxicloroquina en la prevención de la infección por SARS-CoV-2 y de la gravedad de la enfermedad de COVID-19 durante el embarazo
SARS-CoV-2 Ivermectin Navarra-ISGlobal Trial (SAINT)
Estudio piloto para evaluar el potencial de la ivermectina para reducir la transmisión de COVID-19
Encuesta serológica Cendea de Cizur
Cendea de Cizur
CoViproteHCt
Projecte de Recerca en Resposta Immunitària i Epidemiologia de Malalties Infeccioses
Conèixer la propagació. Entendre la protecció
AMR DetecTool
A breakthrough device for the rapid detection of antimicrobial resistance
HBV-COMSAVA
Hepatitis B Virus COMmunity Screening and Vaccination in Africans
Stool4TB
Evaluating a new stool based qPCR for diagnosis of tuberculosis in children and people living with HIV
Hep C Free Baleares
Eliminating hepatitis C on the Balearic Islands (Mallorca, Menorca and Ibiza): a study in governmental and non-governmental addiction service centres, a mobile methadone unit and a prison to test and link people who use drugs to HCV care.
CAPTB
Close the Gap, Increase Access, Provide Adequate Therapy
SAFE (Superbug Awareness For Education)
Second Edition
STREESCO
Strengthening Epidemiological Surveillance in Benin and Burkina Faso for an Effective Response to COVID-19
COVAIR-CAT
Air Pollution in Relation to COVID-19 Morbidity and Mortality: A Large Population-Based Cohort Study in Catalonia
TB-RECONNECT
Reconnecting Transmission to Global Tuberculosis Control by Mapping Pathogen Transmission Events to Host Infection Status
SToolNIH
Quantifiable stool-based TB PCR to Improve Diagnostics and Treatment Monitoring
ALIA
Las ciudades y la salud
END-VOC
ENDing COVID-19 Variants Of concern through Cohort studies (END-VOC)